Researchers clarified a new oncogenic mechanism of enhancer of Zeste Homolog 2 (EZH2) by which it interacted with heterochromatin protein 1 binding protein 3 (HP1BP3) and epigenetically activated WNT7B thereby promoting TMZ resistance in glioma stem cells.
[Oncogene]
